An interventional study of synovial biopsies in Osteoarthritis, sponsored by Nantes University Hospital. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Nantes University Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies in Osteoarthritis with a site in France — 25 open to participants now, 38 under way, 2 of them phase 3. Osteoarthritis · France.
Among the 136 studies in Osteoarthritis with a site in France, this one is the 69th largest by planned enrollment of the 86 interventional ones that give a count, is one of 9 that started in 2026, is one of 48 with no phase, reaches primary completion later than 15 of the 37 other live ones, and was the 132nd registered.
2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →25 of the 136 studies in Osteoarthritis with a site in France are open now. Recruiting first, the newest first:
TBF Genie Tissulaire · Sites in France
Ages 18–75
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 40–85
University Hospital, Montpellier · Sites in France
Ages 75+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Groupe Hospitalier Diaconesses Croix Saint-Simon · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 15 · Phase 4 6
First in 1999; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 80 across 2,242 interventional studies indexed under Osteoarthritis.
Median enrollment 90 across the 86 interventional studies, 152 across the 48 observational. Of the 83 that completed or were terminated, 12 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 136 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 5 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
10 of the studies in Osteoarthritis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06902805Phase 3Assistance Publique - Hôpitaux de ParisEfficacy of Two Ultrasound-guided Intra-articular Injections of Botox® Combined With Custom-made Rigid Splinting in Painful Base-of-thumb Osteoarthritis. | 2027-05 |
| NCT06038331TBF Genie TissulaireUse of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis | 2026-11 |
| NCT07812701Assistance Publique - Hôpitaux de ParisTopical Clobetasol Propionate for Inflammatory Hand Osteoarthritis | 2026-11 |
| NCT02337244Zimmer, GmbHZimmer POLAR Persona - TKA (EMEA Study) | 2026-12 |
| NCT03372278Zimmer BiometPMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 136 studies in Osteoarthritis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Osteoarthritis is a common disease whose prevalence continues to increase. To date, there is no medical treatment that has proven effective, and only symptomatic treatments exist, mainly to reduce pain.
Arthroplasty, a costly and invasive surgical procedure, is often unavoidable in advanced stages of the disease. More than just a degenerative disease of the cartilage, osteoarthritis is now recognised as a heterogeneous disease causing multi-tissue damage of varying intensity. Synovitis plays a particularly important role in the onset and progression of osteoarthritis and has been closely correlated with radiographic severity, pain and loss of joint function. The investigators have identified several synovial histological pathotypes based on the type of synovial cell infiltrate and its distribution in samples from advanced osteoarthritis (surgical waste from prosthesis implantation). The investiogators' studies show that the presence of these pathotypes appears to be related to the clinical phenotype of patients. Analysis of synovial tissue at earlier stages of the disease is now essential to advance the understanding of the role of synovitis in osteoarthritis and its link to the clinical phenotype of patients.
The objective of this protocol is to describe the different synovial histological pathotypes present in the early stages of osteoarthritis; To this end, the investigators will establish a cohort of osteoarthritis patients with a collection of synovial tissue samples obtained by ultrasound-guided needle biopsy in an outpatient setting, a well-tolerated procedure with simple follow-up, as well as blood sampling.
Osteoarthritis is a common disease whose prevalence continues to increase. It results from a variety of factors, such as ageing, excess weight and trauma, for example. To date, there is no medical treatment that has proven effective, and only symptomatic treatments exist, mainly to reduce pain. Arthroplasty, a costly and invasive surgical procedure, is often unavoidable in the advanced stages of the disease. More than just a degenerative disease of the cartilage, osteoarthritis is now recognised as a heterogeneous disease causing multi-tissue damage of varying intensity. Synovitis plays an important role in the initiation and progression of osteoarthritis and has been closely correlated with radiographic severity, pain and loss of joint function. The investigators have identified several synovial histological pathotypes based on the type of synovial cell infiltrate and its distribution in samples of advanced osteoarthritis (surgical waste from prosthesis implantation). The investigators' studies show that the presence of these pathotypes appears to be linked to the clinical phenotype of patients. Analysis of synovial tissue at earlier stages of the disease is now essential to advance our understanding of the role of synovitis in osteoarthritis and its link to the clinical phenotype of patients. The aim of this protocol is to describe the different synovial histological pathotypes present in the early stages of osteoarthritis; To this end, the investigators will establish a cohort of osteoarthritis patients and collect synovial tissue samples via ultrasound-guided needle biopsy in an outpatient setting, a well-tolerated procedure with simple after-effects, as well as blood samples. This procedure will be performed during an intra-articular injection scheduled as part of the patient's treatment. These samples will be used as part of a translational research project funded by the French National Research Agency (ANR). Patients' clinical data will be collected prospectively as part of a cohort study, including clinical and radiographic assessment of osteoarthritis. The objective of the study is to better understand the pathophysiological mechanisms governing the development of osteoarthritis within the synovial membrane in the early stages of the disease, thereby improving its management, identifying new therapeutic targets and paving the way for personalised medicine for patients suffering from osteoarthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of early osteoarthritis defined by the following clinical criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: synovial biopsies
The procedure for performing ultrasound-guided synovial biopsies is as follows: * This is performed under local anaesthetic, in the consultation room, under strict aseptic conditions in five stages. * After tracing anaesthesia up to the capsule, 2 to 3 mL of lidocaine are injected intra-articularly. * A 13G coaxial needle is then positioned in the joint cavity, allowing multiple biopsies to be performed without causing tissue damage along the needle path. * Samples are taken using a 14G semi-automatic Tru-Cut with a notch allowing the collection of 1 mm x 2 cm synovial samples. The aim is to perform histological, immunohistochemical, cell culture and high-throughput analyses. Ideally, 6 to 12 additional biopsies will be performed for research purposes.
describe the different synovial histological pathotypes
describe the different synovial histological pathotypes present in the early stages of osteoarthritis. To this end, we will establish a cohort and a bio-collection of synovial tissue and blood samples (peripheral blood mononuclear cells, PBMC, serum) from patients with early osteoarthritis.
Time frame: During visit inclusion
Histological analyses of tissue to validate its quality
Histological analyses of tissue to validate its quality
Time frame: during visit inclusion
Biopsy tolerance
Pain score \[0 to 10\] reported by the patient to assess the pain experienced during the procedure . 10 being the worst and 0 being the best (no pain). Collection of immediate complications (bleeding, vasovagal episodes, Pain score \[0 to 10\] after the biopsy procedure) .
Time frame: during visit inclusion
Patient acceptability of samples
The following question will be asked on Day 15: Would you be willing to repeat this procedure if necessary?
Time frame: on the 15th day
Histological analyses to quantify synovial inflammatory infiltrate
Time frame: During visit inclusion
Analyses of the relationship between the extent and quality of cellular infiltration in histology and the intensity of synovitis determined by ultrasound
Time frame: During visit inclusion
High-throughput tissue analysis (single-cell sequencing, spatial transcriptomics)
Time frame: During visit inclusion
Effect of in vitro and ex vivo immune cell modulation strategies on synovial membrane explants
Time frame: On the 15th day
Analysis of the relationship between circulating and synovial immune populations
Time frame: During visit inclusion
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.
Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 12 months is below that.
Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.